Compare XYF & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XYF | SABS |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United States |
| Employees | N/A | 63 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.3M | 198.5M |
| IPO Year | 2018 | N/A |
| Metric | XYF | SABS |
|---|---|---|
| Price | $5.25 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 258.2K | ★ 465.5K |
| Earning Date | 03-18-2026 | 03-27-2026 |
| Dividend Yield | ★ 10.97% | N/A |
| EPS Growth | ★ 49.84 | N/A |
| EPS | ★ 5.72 | N/A |
| Revenue | ★ $1,106,908,607.00 | $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.92 | ★ N/A |
| Revenue Growth | ★ 47.14 | N/A |
| 52 Week Low | $4.93 | $1.00 |
| 52 Week High | $20.36 | $6.60 |
| Indicator | XYF | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 32.71 | 45.22 |
| Support Level | $4.93 | $4.27 |
| Resistance Level | $5.40 | $4.68 |
| Average True Range (ATR) | 0.32 | 0.26 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 14.73 | 15.12 |
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.